StockNews.AI
NYXH
StockNews.AI
106 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Nyxoah S.A. - NYXH

1. Investors in Nyxoah facing potential securities fraud claims. 2. FDA issued an Approvable Letter for Nyxoah’s Genio® system. 3. Analysts predict a delay in Genio's commercial launch. 4. Nyxoah's stock fell 21.36% following the FDA announcement. 5. Pomerantz LLP investigating allegations against Nyxoah's leadership.

4m saved
Insight
Article

FAQ

Why Bearish?

The decline of 21.36% in stock value signals market distress and investor uncertainty. Historical parallels exist when FDA delays have led to diminished investor confidence in biotech stocks.

How important is it?

The combination of legal scrutiny and FDA delays amplify uncertainties surrounding NYXH. Legal ramifications can have lasting effects on stock performance.

Why Short Term?

Immediate legal investigations typically affect stock prices in the short term. The delay in product launch may influence market sentiment until resolved.

Related Companies

NDAQAMGNGILD
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Nyxoah S.A. (“Nyxoah” or the “Company”) (NASDAQ: NYXH).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Nyxoah and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On March 25, 2025, Nyxoah issued a press release “announc[ing] that the U.S. Food and Drug Administration (FDA) has issued an Approvable Letter regarding the Company’s Pre-Market Approval (PMA) application for the Genio® system”, which “means that Nyxoah’s application for marketing the device in the United States substantially meets the requirements of the Federal Food, Drug and Cosmetic Act and the FDA’s PMA implementing regulations . . . , and the FDA will approve the application subject to satisfactory completion of a manufacturing facilities, methods and controls review.” Following Nyxoah’s announcement, analysts projected that Genio’s commercial launch would be delayed pending further review by the FDA. On this news, Nyxoah’s stock price fell $2.42 per share, or 21.36%, to close at $8.91 per share on March 26, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News